These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 25661711)

  • 1. An FDA oncology analysis of antibody-drug conjugates.
    Saber H; Leighton JK
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):444-52. PubMed ID: 25661711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates.
    Saber H; Simpson N; Ricks TK; Leighton JK
    Regul Toxicol Pharmacol; 2019 Oct; 107():104429. PubMed ID: 31325532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection.
    Saber H; Del Valle P; Ricks TK; Leighton JK
    Regul Toxicol Pharmacol; 2017 Nov; 90():144-152. PubMed ID: 28887049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.
    Hansen AR; Cook N; Ricci MS; Razak A; Le Tourneau C; McKeever K; Roskos L; Dixit R; Siu LL; Hinrichs MJ
    Oncologist; 2015 Jun; 20(6):653-9. PubMed ID: 25964306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic.
    Stagg NJ; Shen BQ; Brunstein F; Li C; Kamath AV; Zhong F; Schutten M; Fine BM
    Regul Toxicol Pharmacol; 2016 Dec; 82():1-13. PubMed ID: 27773754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety.
    Ryan PC; Sleeman MA; Rebelatto M; Wang B; Lu H; Chen X; Wu CY; Hinrichs MJ; Roskos L; Towers H; McKeever K; Dixit R
    Toxicol Appl Pharmacol; 2014 Sep; 279(2):230-9. PubMed ID: 24937321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Brief Introduction to Antibody-Drug Conjugates for Toxicologic Pathologists.
    Mecklenburg L
    Toxicol Pathol; 2018 Oct; 46(7):746-752. PubMed ID: 30295169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE.
    Jiang J; Li S; Shan X; Wang L; Ma J; Huang M; Dong L; Chen F
    Toxicol Lett; 2020 May; 324():30-37. PubMed ID: 31877330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
    Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An FDA oncology analysis of immune activating products and first-in-human dose selection.
    Saber H; Gudi R; Manning M; Wearne E; Leighton JK
    Regul Toxicol Pharmacol; 2016 Nov; 81():448-456. PubMed ID: 27743776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates.
    Lansita JA; Burke JM; Apgar JF; Mounho-Zamora B
    Pharm Res; 2015 Nov; 32(11):3584-92. PubMed ID: 26108879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
    Liao MZ; Lu D; Kågedal M; Miles D; Samineni D; Liu SN; Li C
    Clin Pharmacol Ther; 2021 Nov; 110(5):1216-1230. PubMed ID: 33899934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
    Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S
    AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies.
    Li C; Zhang C; Li Z; Samineni D; Lu D; Wang B; Chen SC; Zhang R; Agarwal P; Fine BM; Girish S
    MAbs; 2020; 12(1):1699768. PubMed ID: 31852341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody Drug Conjugates: Nonclinical Safety Considerations.
    Hinrichs MJ; Dixit R
    AAPS J; 2015 Sep; 17(5):1055-64. PubMed ID: 26024656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Method development of a novel PK assay for antibody-conjugated drug measurement of ADCs using peptide-linker drug analyte.
    Hyung SJ; Li D; Koppada N; Kaur S; Saad OM
    Anal Bioanal Chem; 2019 May; 411(12):2587-2596. PubMed ID: 30828756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.